Evidence map›Paper›PMID 28704499›Full record

ArticlePloS one2017

The low expression of miR-451 predicts a worse prognosis in non-small cell lung cancer cases.

Akiteru Goto, Masamitsu Tanaka, Makoto Yoshida, Michinobu Umakoshi, Hiroshi Nanjo, Kouya Shiraishi, Motonobu Saito, Takashi Kohno, Sei Kuriyama, Hayato Konno and 4 more

RetractedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Article
  3. Identification of Tumor SuppressiveInternational journal of molecular sciences · 2024
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Akiteru GotoDepartment of Cellular and Organ Pathology, Graduate School of Medicine, Akita University, Akita, Japan.ORCID http://orcid.org/0000-0001-8776-9004
Masamitsu TanakaDepartment of Molecular Medicine and Biochemistry, Graduate School of Medicine, Akita University, Akita, Japan.
Makoto YoshidaDepartment of Cellular and Organ Pathology, Graduate School of Medicine, Akita University, Akita, Japan.
Michinobu UmakoshiDepartment of Cellular and Organ Pathology, Graduate School of Medicine, Akita University, Akita, Japan.
Hiroshi NanjoDepartment of Clinical Pathology, Akita University Hospital, Akita, Japan.
Kouya ShiraishiDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.
Motonobu SaitoDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.
Takashi KohnoDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.
Sei KuriyamaDepartment of Molecular Medicine and Biochemistry, Graduate School of Medicine, Akita University, Akita, Japan.
Hayato KonnoDepartment of Thoracic Surgery, Akita University Hospital, Akita, Japan.
Kazuhiro ImaiDepartment of Thoracic Surgery, Akita University Hospital, Akita, Japan.
Hajime SaitoDepartment of Thoracic Surgery, Akita University Hospital, Akita, Japan.
Yoshihiro MinamiyaDepartment of Thoracic Surgery, Akita University Hospital, Akita, Japan.
Daichi MaedaDepartment of Cellular and Organ Pathology, Graduate School of Medicine, Akita University, Akita, Japan.
Akita University · JPAkita University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposemiR-451 is a tumor suppressive microRNA with several target genes, including Macrophage migration inhibitory factor (MIF). As little is known about the expression and clinicopathological significance of mir-451 in NSCLC, we performed a clinicopathological study of 370 NSCLC cases to clarify them. Cell biological experiments were also performed on NSCLC cell lines to confirm the tumor-suppressive role of miR-451 and whether or not MIF is targeted by miR-451.

methodsWe analyzed 370 NSCLC cases for the miR-451 expression by quantitative real-time polymerase chain reaction and the MIF expression by immunohistochemistry. Eighty-four background lung tissue samples were also evaluated for the miR-451 expression. The clinicopathological and genetic factors surveyed were the disease-free survival, smoking status, histological type, disease stage, EGFR gene mutations and ALK rearrangements. In 286 adenocarcinoma cases, the invasive status (adenocarcinoma in situ, minimally invasive adenocarcinoma and invasive adenocarcinoma) was also evaluated. Five NSCLC cell lines (H23, H441, H522, H1703, and H1975) were cultured and evaluated for their miR-451 and MIF expression. The cell lines with lower miR-451 and higher MIF expressions were then selected and transfected with miR-451-mimic to observe its effects on MIF expression, Akt and Erk status, cell proliferation, and cell migration.

resultsThe miR-451 expression was down-regulated in cancer tissues compared with background lung tissues (P<0.0001). Factors such as advanced disease stage, positive pleural invasion and nodal status and being a smoker were significantly correlated with a lower expression of miR-451 (P<0.05 each), while EGFR gene mutations and ALK rearrangements were not. In adenocarcinoma, invasive and minimally invasive adenocarcinoma showed lower expression of miR-451 than adenocarcinoma in situ (P<0.0005, respectively). A survival analysis showed that a lower expression of miR-451 was an independent predictor of a poor prognosis for NSCLC (P<0.05). The MIF expression was inversely correlated with the miR-451 expression. Out of 5 NSCLC cell lines examined, H441 and H1975 showed higher MIF and lower miR-451 expressions. After the transfection of miR-451-mimic, the MIF expression and phosphorylated Akt expression of these cell lines was suppressed, as were cell proliferation and cell migration.

conclusionThis clinicopathological study of 370 NSCLC cases and the cell biological studies of NSCLC cell lines clarified the tumor-suppressive role of miR-451 and its prognostic value. We also validated MIF as a target of miR-451 in NSCLC.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Non-Small-Cell LungCell Line, TumorDown-RegulationFemaleHumansIntramolecular OxidoreductasesLung NeoplasmsMacrophage Migration-Inhibitory FactorsMaleMicroRNAsMiddle AgedBiomarkers, TumorIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMicroRNAsMIF protein, humanMIRN145 microRNA, human

Identifiers

PMID28704499
PMCPMC5507527
OpenAlexW2735151069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.